

STIC Translation Branch Request Form forPhone: 308-0881 Crystal Plaza ¾, Room 2C15 <http://ptoweb/patents/s>**PTO 2005-5329**

S.T.I.C. Translations Branch

**Information in shaded areas marked with an * is require
Fill out a separate Request Form for each document*****U. S. Serial No. : 10/033,777*****Requester's Name: Mike Meller****Phone No.: 571-272-0967****Office Location: Rem 3C03****Art Unit/Org. : 1654****Is this for the Board of Patent Appeals? yes****Date of Request: 7/25/2005*****Date Needed By: 8/25/2005***(Please indicate a specific date)***Document Identification (Select One):**Note: If submitting a request for patent translation, it is not necessary to attach a copy of the document with the request.If requesting a non-patent translation, please attach a complete, legible copy of the document to be translated to this form and submit it at your EIC or a STIC Library.1. x **Patent** *Document No. JP 02000023696*Country Code JP*Publication Date 1/2000*Language JapaneseNo. of Pages 18 *(filled by STIC)*2. _____ **Article**

*Author _____

*Language _____


*Country _____

3. _____ **Other**

*Type of Document _____

*Country _____

*Language _____

Translations Branch
The world of foreign prior art to you.*To assist us in providing the most cost effective service, please answer these questions:*

- > Will you accept an English Language Equivalent? yes (Yes/No)
- > Would you like to review this document with a translator prior to having a complete written translation?
(Translator will call you to set up a mutually convenient time) no (Yes/No)
- > Would you like a Human-Assisted Machine translation? no (Yes/No)
Human Assisted Machine translations provided by Derwent/Schreiber is the default for Japanese Patents 1993 onwards with an Average 5-day turnaround.

STIC USE ONLY**Copy/Search**

Processor: _____

Date assigned: _____

Date filled: _____

Equivalent found: (Yes/No) _____

Doc. No.: 2269109Country: CA**Translation**Date logged in: 8-1-05

PTO estimated words: _____

Number of pages: _____

In-House Translation Available: _____

In-House

Translator: _____

Assigned: _____

Returned: _____

Contractor:

Name: _____

Priority: _____

Sent: _____

Returned: _____



Query/Command : PRT SS 1 MAX 1-7

1 / 7 PLUSPAT - ©QUESTEL-ORBIT

Patent Number :

CA2269109 A1 19991024 [CA2269109]

Title :

(A1) PROTEASE FOR ACTIVATING CLOTTING FACTOR VII

Other Title :

(A1) PROTEASE POUR AMORCER LE FACTEUR DE COAGULATION VII

Language :

ENGLISH (ENG)

Patent Assignee :

(A1) CENTEON PHARMA GMBH (DE)

Inventor(s) :

(A1) FEUSSNER ANNETTE (DE); ROEMISCH JUERGEN (DE); STOEHR HANS-ARNOLD (DE)

Application Nbr :

CA2269109 19990423 [1999CA-2269109]

Priority Details :

DE19818495 19980424 [1998DE-1018495]
 DE19827734 19980622 [1998DE-1027734]
 DE19851332 19981106 [1998DE-1051332]
 DE19851336 19981106 [1998DE-1051336]
 DE19851335 19981106 [1998DE-1051335]
 DE19903693 19990320 [1999DE-1003693]

*See
Pg. 6.*

Intl Patent Class :

(A1) A61K-038/43 C12N-009/50 C12N-009/96 C12Q-001/37 C12Q-001/56 G01N-033/573 G01N-033/86

Publication Stage :

(A1) Application laid open

Abstract :


A protease for activating the blood clotting factor VII and its proenzyme is described. Moreover, a process for obtaining the protease and its use in hemorrhage prophylaxis or hemostasis is described. A stabilized factor V and a stabilized factor VIII preparation are furthermore described which are free of the inactive factor VIII fragments formed by proteolytic degradation as a result of the inhibition or the removal of the protease activating the blood clotting factor VII. Moreover, a test system for the qualitative and quantitative detection of a protease which activates the blood clotting factor VII is described. Finally, pharmaceutical preparations are described which are suitable for the prophylaxis and treatment of bleeding events, e.g. in the presence of FVIII inhibitors, wound healing and for the treatment of disorders which are caused by fibrin-containing thrombin. The preparations contain the protease activating the blood clotting factor 'VII, or its proenzyme.e

Update Code :

2003-51

2 / 7 PLUSPAT - ©QUESTEL-ORBIT - image

Patent Number :

 US2003152567 A1 20030814 [US20030152567]

Patent Number 2 :

 US6911334 B2 20050628 [US6911334]

Title :

(A1) Protease for activating clotting factor VII

Patent Assignee :

(A1) AVENTIS BEHRING GMBH (US)

Patent Assignee :

ZLB Behring GmbH, Marburg [DE]

Patent Assignee 2 :

(B2) ZLB BEHRING GMBH (DE)

Inventor(s) :

(A1) FEUSSNER ANNETTE (DE); ROEMISCH JUERGEN (DE); STOEHR HANS-ARNOLD (DE)

Application Nbr :

US31959202 20021216 [2002US-0319592]

Filing Details :

Divsn of US09295316 19990421 [1999US-0295316]

Division of: US6528299

Previous Publication: US20030152567 A1 20030814

Priority Details :

US31959202 20021216 [2002US-0319592]

DE19818495 19980424 [1998DE-1018495]

DE19827734 19980622 [1998DE-1027734]

DE19851332 19981106 [1998DE-1051332]

DE19851336 19981106 [1998DE-1051336]

DE19851335 19981106 [1998DE-1051335]

DE19903693 19990320 [1999DE-1003693]

US29531699 19990421 [1999US-0295316]

Intl Patent Class :

(A1) A61K-038/48 C07H-021/04 C12N-005/06 C12N-009/50 C12N-009/64 C12P-021/02
C12Q-001/37

EPO ECLA Class :

A61L-015/38

C07K-014/745

C12N-009/64F2C21

EPO ICO Class :

K61K-038/00

M12N-203/00

US Patent Class :

ORIGINAL (O) : 435219000; CROSS-REFERENCE (X) : 435007100 435013000

514002000 514012000 514021000 530350000 530381000

Document Type :

Corresponding document

Citations :

Cited; FR2504921; WO9101497; WO9610638

Cited by examiner

Harpel et al. , J. Biol. Chem. 265, 11289-11294 (1990).

Cited by applicant

Kazama, Yoshiaki et al., "Hepsin, a Putative Membrane-Associated Serine Protease, Activates Human Factor VII and Initiates a Pathway of Blood Coagulation on the Cell Surface Leading to Thrombin Formation," The Journal of Biological Chemistry, vol. 270 (1), pp. 66-72, (1995).

Choi-Miura, Nam-Ho et al., "Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) From Human Plasma: It has Three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Growth Factor Activator," J. Biochem, vol. 119 (6), pp. 1157-1165 (1996).

Laake, K. et al., "Activation of Purified Plasma Factor VII By Human Plasmin, Plasma Kallikrein, And Activated Components of the Human Intrinsic Blood Coagulation System," Thrombosis Research, vol. 5 (6), pp. 759-772 (1974).

Römisch, J. et al., "A Protease Isolated From Plasma Which Activates FVII in a Tissue Factor Independent Manner But Inactivates FV and FVIII," Annals of Hematology, vol. 78 (1), pp. 24-27 (1999) (Abstract).

Römisch, J. et al., "The FVII Activating Protease Mediates Fibrinolytic Effects Activating Single-Chain Plasminogen Activators," Annals of Hematology, vol. 78 (1), pp. 24-27 (1999) (Abstract).

Hunfeld, A. et al., "Identification of the Thrombin-Like Activity of PCCs," Annals of Hematology, vol. 76 (1), pp. 25-28 (1998) (Abstract).

Choay, SA et al., "Pharmaceutical Complex of Plasmin and Aprotinin -- With Long Lasting Fibrinolytic Activity," Derwent Abstract.

Etscheid et al., 43rd Annual Meeting of the GTH; Supplement 1 to vol. 78 A42, P030 (1999).

Hunfeld et al., 42nd Annual Meeting of the GTH; Supplement 1 to vol. 76 A101, P294 (1998).

Hunfeld et al., 41st Annual Meeting of the GTH; Supplement 1 to vol. 74 A87 P113 (1997).

Römisch et al., 43rd Annual Meeting of the GTH; Supplement 1 to vol. 78 A24, FV079 (1999).

Römisch et al., 43rd Annual Meeting of the GTH; Supplement 1 to vol. 78 A10, FV024

(1999).

Choi-Miura et al., J. Biochem, vol. 119, No. 6, P1157-1165 (1996).

Publication Stage :

(A1) Utility Patent Application published on or after January 2, 2001

Publication Stage 2 :

(B2) U.S. Patent (with pre-grant pub.) after Jan. 2, 2001

Abstract :


A protease for activating the blood clotting factor VII is described, wherein the protease is inhibited by the presence of aprotinin and is increased in its activity by calcium ions and/or heparin or heparin-related substances, and wherein in SDS-PAGE, on subsequent staining in the non-reduced state, the protease has one or more bands in the molecular weight range from 50 to 75 kDa, and in the reduced state, the protease has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa. The proenzyme of this protease is also characterized. Further, a process for obtaining this protease and its use in hemorrhage prophylaxis or hemostasis is described. Moreover, a test system for the qualitative and quantitative detection of a protease which activates the blood clotting factor VII is described.

Update Code :

2003-37

3 / 7 PLUSPAT - ©QUESTEL-ORBIT

Patent Number :

 US6528299 B1 20030304 [US6528299]

Title :

(B1) Protease for activating clotting factor VII

Patent Assignee :

(B1) AVENTIS BEHRING GMBH (DE)

Patent Assignee :

Aventis Behring GmbH, Marburg [DE]

Inventor(s) :

(B1) FEUSSNER ANNETTE (DE); ROEMISCH JUERGEN (DE); STOEHR HANS-ARNOLD (DE)

Application Nbr :

US29531699 19990421 [1999US-0295316]

Priority Details :

DE19818495 19980424 [1998DE-1018495]

DE19851332 19981106 [1998DE-1051332]

DE19851336 19981106 [1998DE-1051336]

DE19851335 19981106 [1998DE-1051335]

DE19903693 19990320 [1999DE-1003693]

DE19827734 19980622 [1998DE-1027734]

Intl Patent Class :

(B1) A61K-038/00 C12N-009/50 C12N-009/64

EPO ECLA Class :

A61L-015/38
C07K-014/745
C12N-009/64F2C21

EPO ICO Class :

K61K-038/00
M12N-203/00

US Patent Class :

ORIGINAL (O) : 435219000; CROSS-REFERENCE (X) : 435006000 435007100
514002000 514012000 514021000 530350000

Document Type :

Corresponding document

Citations :

FR2504921; WO9101497; WO9610638

Kazama, Yoshiaki et al., "Hepsin, a Putative Membrane-Associated Serine Protease, Activates Human Factor VII and initiates a Pathway of Blood Coagulation on the Cell Surface Leading to Thrombin Formation," The Journal of Biological Chemistry, vol. 270 (1), pp. 66-72, (1995).

Choi-Miura, Nam-Ho et al., "Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) From Human Plasma: It Has Three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Growth Factor Activator," J. Biochem, vol. 119 (6), pp. 1157-1165 (1996).

Laake, K. et al., "Activation of Purified Plasma Factor VII By Human Plasmin, Plasma Kallikrein, And Activated Components of the Human Intrinsic Blood Coagulation System," Thrombosis Research, vol. 5 (6), pp. 759-772 (1974).

Romisch, J. et al., "A Protease Isolated From Plasma Which Activates FVII in a Tissue Factor Independent Manner But Inactivates FV and FVII," Annals of Hematology, vol. 78 (1), pp. 24-27 (1999) (Abstract).

Romisch, J. et al., "The FVII Activating Protease Mediates Fibrinolytic Effects Activating Single-Chain Plasminogen Activators," Annals of Hematology, vol. 78 (1), pp. 24-27 (1999) (Abstract).

Hunfeld, A. et al., "Identification of the Thrombin-Like Activity of PCCs," Annals of Hematology, vol. 76 (1), pp. 25-28 (1998) (Abstract).

Choay, Sa et al., "Pharmaceutical Complex of Plasmin and Aprotinin--With Long Lasting Fibrinolytic Activity," Derwent Abstract.

Etscheid et al., 43.sup.rd Annual Meeting of the GTH; Supplement I to vol. 78 A42, P030 (1999).

Hunfeld et al., 42.sup.nd Annual Meeting of the GTH; Supplement I to vol. 76, A101, P294 (1998).

Hunfeld et al., 41.sup.st Annual Meeting of the GTH; Supplement II to vol. 74, A87, P113

(1997).

Romisch et al., 43.sup.rd Annual Meeting of the GTH; Supplement I to vol. 78, A24, FV079 (1999).

Romisch et al., 43.sup.rd Annual Meeting of the GTH; Supplement I to vol. 78, A10, FV024 (1999).

Choi-Miura et al. J. Biochem, vol. 119, No. 6, P1157-1165 (1996).

Publication Stage :

(B1) U.S. Patent (no pre-grant pub.) after Jan. 2, 2001

Abstract :


A protease for activating the blood clotting factor VII, which is inhibited by the presence of aprotinin, is increased in its activity by calcium ions and/or heparin or heparin-related substances, and in SDS-PAGE, on subsequent staining in the non-reduced state, comprises one or more bands in the molecular weight range from 50 to 75 kDa; and in SDS-PAGE, on subsequent staining in the reduced state, comprises a band at 40 to 55 kDa, one or more bands in the molecular weight range from 10 to 35 kDa, and a band in the molecular weight range between 60 and 65 kDa, which corresponds to a proenzyme. Pharmaceutical preparations containing the protease or its proenzyme are suitable for the prophylaxis and treatment of bleeding events, e.g. in the presence of FVIII inhibitors, wound healing and for the treatment of disorders which are caused by fibrin-containing thrombin.

Update Code :

2003-12

4 / 7 PLUSPAT - ©QUESTEL-ORBIT

Patent Number :

 JP2000023696 A 20000125 [JP2000023696]

Title :

PROTEASE FOR ACTIVATING CLOTTING FACTOR VII

Patent Assignee :

(A) CENTEON PHARMA GMBH

Inventor(s) :

(A) ROEMISCH JUERGEN DR; STOEHR HANS-ARNOLD; FEUSSNER ANNETTE

Application Nbr :

JP11641199 19990423 [1999JP-0116411]

Priority Details :

DE19818495 19980424 [1998DE-1018495]

DE19827734 19980622 [1998DE-1027734]

DE19851332 19981106 [1998DE-1051332]

DE19851335 19981106 [1998DE-1051335]

DE19851336 19981106 [1998DE-1051336]

DE19903693 19990320 [1999DE-1003693]

Intl Patent Class :

(A) A61K-031/00 A61K-038/46 C12N-009/50 C12Q-001/37 C12Q-001/56 G01N-033/566

G01N-033/573

Publication Stage :

(A) Doc. Laid open to publ. Inspec.

Abstract :



PROBLEM TO BE SOLVED: To provide a protease for activating the clotting factor VII, to provide a method for isolating it, detecting it and inactivating it, and to provide medical preparations comprising the protease.

SOLUTION: This protease and its zymogen have the following properties: (1) being inhibited by the existence of aprotinin; (2) increasing the activity due to calcium ions and/or heparin (or its analogue); (3) showing one or plural bands in the range of 50-75 kDa molecular weight in subsequently dyeing in a nonreduced state and one or plural bands in the range of 10-35 kDa molecular weight in a reduced state respectively according to a SDS-PAGE method; (4) activating the blood coagulation factor VII. The protease and its zymogen are prepared by subjecting blood plasma or prothrombin complex (PPSB) concentrate to anion exchange chromatography preliminarily and then by subjecting the product to affinity chromatography using heparin (or its analogue) or dextran sulfuric acid.

COPYRIGHT: (C)2000,JPO

Update Code :

2000-49

*5 / 7 PLUSPAT - ©QUESTEL-ORBIT***Patent Number :** AU2393599 A 19991104 [AU9923935]**Patent Number 2 :** AU748221 B2 20020530 [AU-748221]**Title :**

(A) Protease for activating clotting factor VII

Patent Assignee :

(A) CENTEON PHARMA GMBH

Patent Assignee 2 :

(B2) AVENTIS BEHRING GMBH

Inventor(s) :

(A) ROMISCH JURGEN; FEUSSNER ANNETTE; STOHR HANS-ARNOLD

Application Nbr :

AU2393599 19990423 [1999AU-0023935]

Priority Details :

DE19818495 19980424 [1998DE-1018495]

DE19827734 19980622 [1998DE-1027734]

DE19851332 19981106 [1998DE-1051332]

DE19851335 19981106 [1998DE-1051335]

DE19851336 19981106 [1998DE-1051336]

DE19903693 19990320 [1999DE-1003693]

Intl Patent Class :

(A) A61K-038/48 A61K-038/55 C12N-009/50 C12Q-001/37 C12Q-001/56 G01N-033/577

G01N-033/86

Publication Stage :


(A) Open to public inspection

Publication Stage 2 :

(B2) Patent preceded by A1

6 / 7 PLUSPAT - ©QUESTEL-ORBIT

Patent Number :

 DE19903693 A1 19991028 [DE19903693]

Other Title :

(A1) Protease zur Aktivierung des Gerinnungsfaktors VII

Patent Assignee :

(A1) CENTEON PHARMA GMBH (DE)

Inventor(s) :

(A1) ROEMISCH JUERGEN (DE); FEUSNER ANNETTE (DE); STOEHR HANS-ARNOLD (DE)

Application Nbr :

DE19903693 19990320 [1999DE-1003693]

Priority Details :

DE19903693 19990320 [1999DE-1003693]

DE19818495 19980424 [1998DE-1018495]

DE19827734 19980622 [1998DE-1027734]

DE19851332 19981106 [1998DE-1051332]

DE19851336 19981106 [1998DE-1051336]

DE19851335 19981106 [1998DE-1051335]

Intl Patent Class :

(A1) A61K-038/48 C12N-009/48 C12N-009/96 C12Q-001/56

EPO ECLA Class :

A61L-015/38

C07K-014/745

C12N-009/64F2C21

EPO ICO Class :

M12N-201/00

M12N-203/00

Document Type :


Corresponding document

Publication Stage :

(A1) Doc. Laid open (First publication)

7 / 7 PLUSPAT - ©QUESTEL-ORBIT

Patent Number :

 EP0952215 A2 19991027 [EP-952215]

Patent Number 2 :

EP0952215 A3 20020626 [EP-952215]

Title :

(A2) Protease for activating clotting factor VII

Other Title :

(A2) Protease zum Aktivierung des Gerinnungsfaktor VII

(A2) Protéase pour l'activation du facteur de coagulation VII

Language :

ENGLISH (ENG)

Patent Assignee :

(A2) CENTEON PHARMA GMBH (DE)

Patent Assignee 2 :

(A3) AVENTIS BEHRING GMBH (DE)

Inventor(s) :

(A2) ROEMISCH JUERGEN DR (DE); FEUSSNER ANNETTE (DE); STOEHR HANS-ARNOLD (DE)

Application Nbr :

EP99106913 19990408 [1999EP-0106913]

Priority Details :

DE19818495 19980424 [1998DE-1018495]

DE19827734 19980622 [1998DE-1027734]

DE19851332 19981106 [1998DE-1051332]

DE19851336 19981106 [1998DE-1051336]

DE19851335 19981106 [1998DE-1051335]

DE19903693 19990320 [1999DE-1003693]

Intl Patent Class :

(A2) A61K-038/48 A61K-038/49 A61K-038/57 A61L-015/38 C07K-014/745 C07K-016/40 C12N-009/64 C12Q-001/37 G01N-033/86

EPO ECLA Class :

A61L-015/38

C07K-014/745

C12N-009/64F2C21

EPO ICO Class :

M12N-203/00

M12N-215/00

Designated States :

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Document Type :

Basic

Citations :

Cited in the search report

WO9101497(A)(Cat. X); FR2504921(A)(Cat. X); WO9610638(A)(Cat. X)

RÖMISCH J. ET AL.: "A protease isolated from plasma which activates FVII in a tissue factor independent manner but inactivates FV and FVIII" ANNALS OF HEMATOLOGY,

- vol. 78, no. Suppl.1, 24 - 27 February 1999, page A10 XP001059496(Cat. X,P,O)
 RÖMISCH J. ET AL.: "The FVII activating protease mediates fibrinolytic effects activating single-chain plasminogen activators" ANNALS OF HEMATOLOGY, 24 - 27 February 1999, page A24 XP001059495(Cat. X,P,O)
 KAZAMA ET AL.: "Hepsin, a putative membrane-associated serine protease, activates human Factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 1, 6 January 1995 (1995-01-06), pages 66-72, XP002190032(Cat. X)
 CHOI-MIURA ET AL.: "Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a Kringle and a serine protease domain, similar to Hepatocyte Growth Factor Activator" JOURNAL OF BIOCHEMISTRY, vol. 119, no. 6, 1996, pages 1157-1165, XP000960750(Cat. A,D)
 HUNFELD A ET AL.: "Identification of the thrombin-like activity of PCCs" ANNALS OF HEMATOLOGY, vol. 76, no. Suppl.1, 25 - 28 February 1998, page A101 XP001059492(Cat. A,D,O)
 LAAKE K & OSTERUD B: "Activation of purified plasma factor VII by human plasmin, plasma kallikrein and activated components of the human intrinsic blood coagulation system" THROMBOSIS RESEARCH, vol. 5, no. 6, December 1974 (1974-12), pages 759-772, XP008000261(Cat. A)
 Revealed during examination
 HUNFELD A. ET AL: 'Detection of a novel plasma serine protease during purification of vitamin K-dependent coagulation factors' FEBS LETTERS vol. 456, 1999, pages 290 - 294 (Cat. A)
 RÖMISCH J. ET AL: 'A protease isolated from human plasma activating Factor VII independent of tissue factor' BLOOD COAGULATION AND FIBRINOLYSIS vol. 10, no. 8, 1999, pages 471 - 479(Cat. A)

Publication Stage :

(A2) Pub. Of applic. Without search report

Publication Stage 2 :

(A3) Publi. Of search report

Abstract :

A protease for activating the blood clotting factor VII is described, which

- a) is inhibited by the presence of aprotinin,
- b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and
- c) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more bands in the molecular weight range from 50 to 75 kDa and kDa in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa.

The proenzyme of this protease is also characterized. Moreover, a process for obtaining this protease and its use in hemorrhage prophylaxis or hemostasis is described. A stabilized factor V and a stabilized factor VIII preparation are furthermore described which are free of the inactive factor VIII fragments formed by proteolytic degradation as a result of the inhibition or the removal of the protease activating the blood clotting factor VII.

Search statement 2